Clinical value of NGAL, L-FABP and albuminuria in predicting GFR decline in type 2 diabetes mellitus patients.
about
Urinary Biomarkers in the Assessment of Early Diabetic NephropathyBiomarkers of Renal Disease and Progression in Patients with DiabetesDiabetic Nephropathy: New Risk Factors and Improvements in DiagnosisDiabetic nephropathy - complications and treatment.Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitusDiagnosis and Prediction of CKD Progression by Assessment of Urinary PeptidesEffects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating tIncreased plasma kidney injury molecule-1 suggests early progressive renal decline in non-proteinuric patients with type 1 diabetes.Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study.Urine Injury Biomarkers and Risk of Adverse Outcomes in Recipients of Prevalent Kidney Transplants: The Folic Acid for Vascular Outcome Reduction in Transplantation Trial.Is Urinary NGAL Determination Useful for Monitoring Kidney Function and Assessment of Cardiovascular Disease? A 12-Month Observation of Patients with Type 2 Diabetes.Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy.Proteomic urinary biomarker approach in renal disease: from discovery to implementation.Novel urinary biomarkers in early diabetic kidney disease.Urinary proteomics and molecular determinants of chronic kidney disease: possible link to proteases.Biomarkers in diabetic nephropathy: Present and future.Body fluid peptide and protein signatures in diabetic kidney diseases.The Promise of Mesenchymal Stem Cell Therapy for Diabetic Kidney Disease.Urine liver fatty acid binding protein and chronic kidney disease progression.Urinary Neutrophil Gelatinase-Associated Lipocalin Is Complementary to Albuminuria in Diagnosis of Early-Stage Diabetic Kidney Disease in Type 2 Diabetes.Epidermal growth factor as a prognostic biomarker in chronic kidney diseases.Serum NGAL and Cystatin C Comparison With Urinary Albumin-to-Creatinine Ratio and Inflammatory Biomarkers as Early Predictors of Renal Dysfunction in Patients With Type 2 Diabetes.Urinary L-FABP as a marker of vesicoureteral reflux in children: could it also have a protective effect on the kidney?Serum Adipocyte Fatty Acid-Binding Protein 4 Levels Are Independently Associated with Radioisotope Glomerular Filtration Rate in Type 2 Diabetic Patients with Early Diabetic Nephropathy.
P2860
Q26740305-A2E7C3C1-736E-441B-AF25-E535A5659647Q26799505-FE3108B9-05A3-4469-8B46-805EAFB6564CQ33583018-62CD446B-D917-4EBF-A51A-30DFF21DC634Q34387952-A0EC9612-D811-4B40-9D7E-A56EE856217DQ34644160-E0FC313E-76E5-4C93-980A-D8875278CEEEQ35903097-7DE9A5AA-F531-4B92-B9E7-C28CC53F5E2FQ36086582-62D93059-F773-45C6-A3F1-2497B16A8549Q36844894-64273A1E-1A55-4774-8283-981A99506E32Q36907473-C0E9BC89-DFD4-4E46-A194-95EBB2EF26DAQ37051993-D3B95456-A58E-4C02-9044-161D93E8CEC7Q37512638-E4BC0926-CA0A-4716-A9DC-591A4328E9DDQ37603244-121C0E2D-A759-42D2-88BE-8C3D36E106F9Q38196316-8C5D00CF-7B28-49BB-89A7-C8AB1534AA68Q38219572-20E12E74-3127-4B6B-B8D7-B8F27B238458Q38222628-30654EB2-B5F3-4CBB-A054-13B79C34E21BQ38290083-3184CC30-4BB0-4DB9-B4F8-70C9B9086FC1Q38553924-1CDC4CC9-98D5-492A-9658-271982EAAC03Q38786133-691876D1-06B6-44BD-B000-E19B71C2719EQ40107790-4B08B664-80DA-45FF-8B78-9BCE684FF8C9Q41463382-2D200B73-0289-456D-BCC5-BF666D716762Q42106829-B8F91213-3530-4FAD-84BE-9D1EAC3B6199Q47136591-B5084604-58FB-4C62-8E2B-1FACCC107017Q48101168-381CD535-5202-4265-966C-C46B8B55B085Q55476340-37B58C4D-D33D-4C07-A8B0-352BF62C1CA7
P2860
Clinical value of NGAL, L-FABP and albuminuria in predicting GFR decline in type 2 diabetes mellitus patients.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Clinical value of NGAL, L-FABP ...... 2 diabetes mellitus patients.
@ast
Clinical value of NGAL, L-FABP ...... 2 diabetes mellitus patients.
@en
Clinical value of NGAL, L-FABP ...... 2 diabetes mellitus patients.
@nl
type
label
Clinical value of NGAL, L-FABP ...... 2 diabetes mellitus patients.
@ast
Clinical value of NGAL, L-FABP ...... 2 diabetes mellitus patients.
@en
Clinical value of NGAL, L-FABP ...... 2 diabetes mellitus patients.
@nl
prefLabel
Clinical value of NGAL, L-FABP ...... 2 diabetes mellitus patients.
@ast
Clinical value of NGAL, L-FABP ...... 2 diabetes mellitus patients.
@en
Clinical value of NGAL, L-FABP ...... 2 diabetes mellitus patients.
@nl
P2093
P2860
P1433
P1476
Clinical value of NGAL, L-FABP ...... 2 diabetes mellitus patients.
@en
P2093
Chiao-Yin Sun
Chih-Huang Chen
Chin-Chan Lee
Kuei-Mei Chou
P2860
P304
P356
10.1371/JOURNAL.PONE.0054863
P407
P577
2013-01-22T00:00:00Z